A

Low-molecular-weight heparin (e.g., dalteparin, enoxaparin) is the standard first-line therapy for cancer-associated venous thromboembolism because it lowers the risk of recurrent events compared with warfarin without increasing major bleeding, as shown in the CLOT trial and incorporated into major guidelines [Rodger, 2006, PMID 16553136].